We specialise in Parkinson’s disease, motor neuron disease; MND (amyotrophic lateral sclerosis; ALS) and neuroinflammation assays.

  • Capacity in preclinical drug testing (efficacy) indisease models, or target validation studies.
  • Range of state-of-the-art disease models accepted by funders and regulators as best-practice preclinical efficacy models.
  • An extensive range of both standardised and novelbehavioural and pathological analyses that can becustomised to suit individual requirements.
  • Can be coupled with pharmacodynamic and pharmacokinetic data from the same animal to maximisedata output and assay validation.
  • Successful record in completing industry contracts,with two drugs undergoing human clinical trialsafter successful testing in preclinical models.
  • Strong publication track record in preclinical neurodegenerative disease animal studies.
  • Offer opportunities for leverage funding throughnon-diluting grant funding.
  • Competitive rates for both fee-for-service or collaborative research projects.

In vivo models available

  • Neuroinflammation endotoxin model (peripheral orcentral induction)
  • Parkinson’s disease 6-hydroxydopamine (6-OHDA) model
  • Parkinson’s disease synuclein pre-formed fibril (PFF-Syn) model
  • Motor neuron disease SOD1G93A transgenic mouse model
  • Motor neuron disease TDP43-transgenic mouse models

In vitro/ex vivo models available

  • Primary human microglia neuroinflammation assays (derived from human blood)
  • Primary mouse microglia neuroinflammation assays (derived from mice CNS tissue)

Neurotransmitter/Neurochemical Quantitation

  • We offer new methods to simultaneously measure a range of neurotransmitters and metabolites from any sample.
  • We utilise state-of-the-art LC-MS/MS methodology to provide full quantitation of analytes coupled with standard curves.
  • We have the ability to determine concentrations in a wide range of biological fluids or tissues from any animal or human species.
  • Analyses can be easily coupled with efficacy studies in neurodegenerative disease or psychiatry models to allow fullquantitation of drug activities.

Currently available as fully-quantitated neurotransmitters:

  • 3,4-Dihydroxymandelic acid
  • 3,4-Dihydroxyphenylacetic acid
  • 3,4-Dihydroxyphenylalanine
  • 3,4-Dihydroxyphenylglycol
  • 3-Hydroxyanthranilic acid
  • 3-Hydroxykynurenine
  • 3-Meth-4-hydroxyphenylglycol
  • 3-Methoxytyramine
  • 4-Aminobutyric acid
  • 5-Hydroxyindoleacetic acid
  • 5-Hydroxytryptophan
  • 5-Hydroxytryptophol
  • 5-Methyltetrahydrofolic acid
  • Acetylcholine
  • Adenosine
  • Agmatine
  • Alanine
  • Anserine
  • Arginine
  • Asparagine
  • Aspartate
  • B-Alanine
  • N-Acetylputrescine
  • N-Acetylserotonin
  • Biotin
  • Betaine
  • Carnosine
  • Choline
  • Citrulline
  • Cysteic acid
  • Cysteine
  • Dimethyl glycine
  • Dihydroxybenzoic acid
  • Dopamine
  • Epinephrine
  • Ethanolamine
  • Folic Acid
  • Glucose
  • Glutamate
  • Glutamine
  • Glutathione
  • Glycine
  • Histamine
  • Histidine
  • Homocysteic acid
  • Homocysteine
  • Homoserine
  • Homovanillic acid
  • Hypotaurine
  • Kynurenic acid
  • Kynurenine
  • Kyotorphin
  • Leucine
  • Lysine
  • Leucine/isoleucine
  • Methionine
  • Nicotinamide
  • Neopterin
  • Norepinephrine
  • Normetanephrine
  • Octopamine
  • Ornithine
  • Pantothenic acid (B5)
  • Phenethylamine
  • Phenylalanine
  • Proline
  • Putrescine
  • Pyridoxine
  • Riboflavin
  • Serine
  • Serotonin
  • Spermidine
  • Spermine
  • Synephrine
  • Taurine
  • Thiamine
  • Threonine
  • Tryptamine
  • Tryptophan
  • Tyramine
  • Tyrosine
  • Valine
  • Vanillylmandelic acid
  • Vitamin B12

Also currently available as fully-quantitated short-chain fatty acids and metabolites

  • Acetic acid
  • Propionic Acid
  • Isobutyric Acid
  • Butyric Acid
  • 2-methylbutanoic acid
  • Valeric Acid
  • 3-methyl-valeric acid
  • hexanoic acid
  • 3-OH-butyric acid
  • Acetoacetate
  • 4-methylvaleric acid
  • Isovaleric acid